Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baclofen for self-induced vomiting behavior in bulimia nervosa
IRCT20260416069082N1Phase 3Recruiting
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bulimia nervosa (BN) comparing Baclofen with Placebo (2 arms). Primary endpoint: Intentional vomiting per week. Started Sep 2026; status: recruiting.
02
Drugs
baclofen
03
Conditions
bulimia nervosa (BN)
Beyond the preview
Go deeper on IRCT20260416069082N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260416069082N1.